PetCaseFinder

Peer-reviewed veterinary case report

Palmitoyl-glucosamine with curcumin helps keep pain down in dogs

By Della Rocca, Giorgia et al.·Published in BMC veterinary research·2023·Department of Veterinary Medicine, Italy·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Palmitoyl-glucosamine co-micronized with curcumin for maintenance of meloxicam-induced pain relief in dogs with osteoarthritis pain.

Species:
dog

Plain-English summary

A group of dogs with osteoarthritis (OA) pain were given a combination of palmitoyl-glucosamine and curcumin while gradually reducing their meloxicam (a common pain medication) dosage. Most dogs were able to lower their meloxicam dose by 25% without experiencing increased pain, and many showed no signs of worsening pain even ten weeks after stopping meloxicam completely. Owners and vets noted significant improvements in pain levels and lameness during the study. This suggests that adding palmitoyl-glucosamine and curcumin to their diet can help maintain pain relief in dogs with OA.

People also search for: dog osteoarthritis treatment · palmitoyl-glucosamine for dogs · curcumin for dog pain relief

Abstract

BACKGROUND: Osteoarthritis (OA) pain is the number one cause of chronic pain in dogs. Multimodal treatment, including combining safe and effective nutritional interventions with non-steroidal anti-inflammatory drugs (NSAIDs), is currently considered one of the most appropriate choices for managing OA pain. Palmitoyl-glucosamine is a feed material belonging to the ALIAmide family, whose parent molecule is the prohomeostatic lipid amide N-palmitoyl-ethanolamine. Curcumin is a promising plant antioxidant. The present study aimed at investigating whether 18-week dietary integration with palmitoyl-glucosamine co-micronized with curcumin was able to maintain pain relief in dogs with OA-associated chronic pain receiving meloxicam (1.5&#xa0;mg/ml oral suspension) on a tapering regimen (progressive 25% decrease of the original 0.1&#xa0;mg/kg/day dose, on a biweekly basis) during the first 8&#xa0;weeks of treatment. Pain was assessed both by the owners and veterinary surgeons, with the first using both subjective evaluation and validated metrology instruments-i.e., Helsinki Chronic Pain Index (HCPI) and Canine Brief Pain Inventory (CBPI)-while the second rating the severity of lameness and pain on palpation on two previously used 5-point scales. RESULTS: A total of fifty-eight dogs with OA chronic pain entered the uncontrolled study. Pain on HCPI was considered severe at baseline (range 18-39). Based on owner's assessment, 90% of dogs who responded to meloxicam at the full-dose regimen could reduce meloxicam up to 25% of the original dose without experiencing pain worsening. Moreover, 75% of dogs was assessed as having no pain increase ten weeks after meloxicam withdrawal. A statistically significant decrease of pain severity as scored by HCPI (P&#x2009;<&#x2009;0.0001) was observed two and ten weeks after meloxicam withdrawal compared to study entry (17.0&#x2009;&#xb1;&#x2009;1.05 and 15.1&#x2009;&#xb1;&#x2009;1.02, respectively, vs 29.0&#x2009;&#xb1;&#x2009;0.74; mean&#x2009;&#xb1;&#x2009;SEM). After meloxicam withdrawal, no statistically significant change in the CBPI scores was recorded. Pain on palpation and lameness significantly changed to less severe distributions along the study period (P&#x2009;<&#x2009;0.0001). CONCLUSION: The findings appear to suggest that dietary integration with palmitoyl-glucosamine co-micronized with curcumin was able to maintain meloxicam-induced pain relief in dogs with severe OA chronic pain.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/36747264/